Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

NCT05380635 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT05380635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05380635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment
Lead sponsor
Soligenix
Phase
Phase 2
Overall status
Completed
Start date
May 9, 2022
Completion date
August 16, 2022
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma/mycosis fungoides